What Role Does Equity Play in Australia’s Health Technology Assessment Processes? A Review of the Pharmaceutical Benefits Advisory Committee Recommendations Regarding Vaccines

Despite increasing mentions of many equity-relevant dimensions, limited equity-informative economic evaluation methods are being used in vaccine submissions. This review provides a pivotal opportunity to advocate for (1) a better understanding of decision makers' needs and preferences around the integration of equity-informative methods, (2) greater transparency and more detailed documentation of deliberations, and (3) clearer guidance on presenting equity-relevant evidence in submissions.